ReviewMalaria journal2011
Plasmodial sugar transporters as anti-malarial drug targets and comparisons with other protozoa.
Review in Malaria journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 52 citations in OpenAlex.
- Selective targeting ofAntimicrobial agents and chemotherapy · 2026Article
- Glucose-functionalized redox-responsive dihydroartemisinin prodrug nanosystem for targeted malaria therapy.International journal of pharmaceutics: X · 2025Article
- An overview of the Plasmodium falciparum hexose transporter and its therapeutic interventions.Proteins · 2022Review
- Targeting theHeliyon · 2022Review
- In vitro and in silico assessment of new beta amino ketones with antiplasmodial activity.Revista da Sociedade Brasileira de Medicina Tropical · 2022Article
- Orthosteric-allosteric dual inhibitors of PfHT1 as selective antimalarial agents.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Article
- Antimalarials with Benzothiophene Moieties as Aminoquinoline Partners.Molecules (Basel, Switzerland) · 2017Article
- GLUT1-mediated glucose uptake plays a crucial role during Plasmodium hepatic infection.Cellular microbiology · 2017Article
- The Glucose Transporter PfHT1 Is an Antimalarial Target of the HIV Protease Inhibitor Lopinavir.Antimicrobial agents and chemotherapy · 2015Article
- Article
- Targeting zinc homeostasis to combat Aspergillus fumigatus infections.Frontiers in microbiology · 2015Article
- Article
- Lipid dependencies, biogenesis and cytoplasmic micellar forms of integral membrane sugar transport proteins of the bacterial phosphotransferase system.Microbiology (Reading, England) · 2013Review
- Bioinformatic characterization of the 4-Toluene Sulfonate Uptake Permease (TSUP) family of transmembrane proteins.Biochimica et biophysica acta · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
Abstract
Glucose is the primary source of energy and a key substrate for most cells. Inhibition of cellular glucose uptake (the first step in its utilization) has, therefore, received attention as a potential therapeutic strategy to treat various unrelated diseases including malaria and cancers. For malaria, blood forms of parasites rely almost entirely on glycolysis for energy production and, without energy stores, they are dependent on the constant uptake of glucose. Plasmodium falciparum is the most dangerous human malarial parasite and its hexose transporter has been identified as being the major glucose transporter. In this review, recent progress regarding the validation and development of the P. falciparum hexose transporter as a drug target is described, highlighting the importance of robust target validation through both chemical and genetic methods. Therapeutic targeting potential of hexose transporters of other protozoan pathogens is also reviewed and discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.